Navigation Links
The dietary supplement genistein can undermine breast cancer treatment
Date:9/23/2008

is treatment (Letrozole) effectively blocked the effects of AD and the breast cancer tumors stopped growing.

But when they added genistein (a plant estrogen or "phytoestrogen" present in many dietary supplements) to the mix, the researchers observed a dose-dependent reduction in the effectiveness of the breast cancer drug. Specifically, the tumors began to grow again. They grew fastest at the highest dietary doses of genistein.

"To think that a dietary supplement could actually reverse the effects of a very effective drug is contrary to much of the perceived benefits of soy isoflavones, and unsettling," said William Helferich a professor of food science and human nutrition at Illinois and principal investigator on the study. "You have women who are taking these supplements to ameliorate post-menopausal symptoms and assuming that they are as safe as consuming a calcium pill or a B vitamin."

Many women take genistein supplements to control hot flashes and other symptoms of menopause. The researchers found that the doses commonly available in dietary supplements were potent enough to negate the effectiveness of aromatase inhibitors.

"These compounds have complex biological activities that are not fully understood," Helferich said. "Dietary supplements containing soy-based phytoestrogens provide high enough dosages that it could be a significant issue to breast cancer patients and survivors."

Plant estrogens from soy are not the only ones of concern, Helferich said. In a recent study, he and his colleagues found that certain mixtures of estrogenic botanical components and extracts marketed as supplements to assist "female libido enhancement" and sold without a prescription appeared to spur breast cancer tumor growth at low doses, while having no effect on tumors at high doses.

That study appeared last year in Food and Chemical Toxicology.

"We are just starting to understand the complex effects of the
'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Researchers uncover details about how dietary restriction slows down aging
2. Market testing of dietary supplements and drugs underscores value of USPs public health programs
3. Changing the global dietary environment
4. Dietary calcium could possibly prevent the spread of breast cancer to bone
5. UF scientists reveal how dietary restriction cleans cells
6. L-1 Identity Solutions to Hold Supplemental Second Quarter 2008 Financial Results Q&A Conference Call at 2:00p.m. (ET) Today
7. Researchers identify cancer preventive properties in common vitamin supplement
8. A nutritional supplement could improve the clinical situation of ICU patients
9. People with diabetes may have all natural citrus supplement
10. Wellmune WGP supplementation alleviates
11. Pediatricians alerted to the developmental nature of underage drinking in special journal supplement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The dietary supplement genistein can undermine breast cancer treatment
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... release is available in German . ... infants was investigated using the prominent ,Stanford Marshmallow Experiment,: the children ... eat it now or wait and receive a second one if ... several minutes. Interestingly, children that were able to wait for the ...
... March 13, 2013, Shenzhen, China - In a collaborative study ... Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, ... of wild rice Oryza brachyantha . This work provides ... of Oryza genomes. The genus Oryza ...
... up and walked on two legs is considered to be one ... gone to the far ends of the earth and the ... we walk the way we walk. In the latest such ... Africa) have taken a closer look at bipedal kangaroos and wallabies ...
Cached Biology News:Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2It's all in the way we move 2
(Date:4/28/2015)... 2015 According to a 2013 report ... receive medical treatment from burn injuries per year. Despite ... extensive formation of scars with subsequent contractures remains a ... which there is no adequate treatment. Contractures are a ... and can cause permanent deformity. , Synedgen has ...
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... 27, 2015  For about a century, a ... ability to utilize and catabolize glucose at a ... is called the ,Warburg phenomenon", that is an ... oxygen presence, leading to enhanced lactate generation. Even ... choose glucose fermentation. A variety of such abnormalities ...
(Date:4/27/2015)... San Diego, Calif. (PRWEB) April 27, 2015 ... mechanisms of drug and chemical toxicity carries implications for ... featured speaker April 28 at National University , ... reception and presentation by Dr. Hanzlik, a professor at ... in drug metabolism and drug design, starts at 5 ...
Breaking Biology Technology:Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... ,, BEIJING, China , May ... or the "Company") a leading developer,manufacturer, and distributor of Shengmingsu brand ... ("PRC"), today announced its,financial results for the quarter ended ... 2010 Highlights, -- Revenue increased 100.5% to $24.9 ...
... RESEARCH TRIANGLE PARK, N.C. , May 12 The International ... Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES).  IES ... early breast cancer and a median follow-up period of 91 months. ... from multiple centers. , , ...
... schedule , , , ... , , ... announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a ... of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and ...
Cached Biology Technology:Yongye International Announces First Quarter 2010 Results 2Yongye International Announces First Quarter 2010 Results 3Yongye International Announces First Quarter 2010 Results 4Yongye International Announces First Quarter 2010 Results 5Yongye International Announces First Quarter 2010 Results 6Yongye International Announces First Quarter 2010 Results 7Yongye International Announces First Quarter 2010 Results 8Yongye International Announces First Quarter 2010 Results 9Yongye International Announces First Quarter 2010 Results 10Yongye International Announces First Quarter 2010 Results 11Yongye International Announces First Quarter 2010 Results 12Yongye International Announces First Quarter 2010 Results 13Yongye International Announces First Quarter 2010 Results 14Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2Resverlogix Completes Dosing for ASSERT Trial 2Resverlogix Completes Dosing for ASSERT Trial 3Resverlogix Completes Dosing for ASSERT Trial 4Resverlogix Completes Dosing for ASSERT Trial 5